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Abstract
Among people living with HIV (PLWH), adherence to antiretroviral therapy (ART) is crucial for health, but
patients face numerous challenges achieving sustained lifetime adherence. We conducted six focus groups with
56 PLWH regarding ART adherence barriers and collected sociodemographics and ART histories. Participants
were recruited through clinics and AIDS service organizations in North Carolina. Dedoose software was used to
support thematic analysis. Participants were 59% male, 77% black, aged 23–67 years, and living with HIV 4–20
years. Discussions reflected the fluid, complex nature of ART adherence. Maintaining adherence required
participants to indefinitely assert consistent control across multiple areas including: their HIV disease, their own
bodies, health care providers, and social systems (e.g., criminal justice, hospitals, drug assistance programs).
Participants described limited control over treatment options, ART’s impact on their body, and inconsistent
access to ART and subsequent inability to take ART as prescribed. When participants felt they had more
decision-making power, intentionally choosing whether and how to take ART was not exclusively a decision
about best treating HIV. Instead, through these decisions, participants tried to regain some amount of power and
control in their lives. Supportive provider relationships assuaged these struggles, while perceived side-effects
and multiple co-morbidities further complicated adherence. Adherence interventions need to better convey
adherence as a continuous, changing process, not a fixed state. A perspective shift among care providers could
also help address negative consequences of the perceived power struggles and pressures that may drive patients
to exert control via intentional medication taking practices.
Introduction
Among people living with HIV (PLWH), timely ini-tiation of antiretroviral therapy (ART) and adherence to
therapy as prescribed are crucial for better individual health
outcomes.1,2 In the United States (US), only about a third of
persons diagnosed with HIV are on ART, and of these, only
54–75% are virally suppressed.3,4
Advances in HIV pharmacotherapy have greatly extended
patients’ lives and simplified available medication regimens
by reducing the number of pills and doses per day, alleviating
severe side effects, and expanding treatment options.5 A
quarter of annual new HIV infections are among those ages
13–24 years old,6 a group that—on therapy—can expect to
live a near-normal life span into their 70s.7 At the same time,
over one-fifth of HIV-infected persons in the US are over age
508 and dealing with the physical and psychosocial chal-
lenges of multiple co-morbidities and medications.9–12 Both
of these phenomena pose challenges for long-term, optimal
adherence.
In order to maximize the benefit from continued advances in
HIV pharmacotherapy, the research and clinical care commu-
nity must adapt care management approaches to the challenges
patients face in achieving sustained, daily adherence in the
context of HIV infection as a life-long condition alongside other
chronic and acute health conditions. Much attention has fo-
cused on developing practical tools to support adherence (e.g.,
directly observed therapy, alarm devices, pill organizers)13 and
evidence-based interventions have included skill building, so-
cial support, and cognitive-behavioral components.14 Persistent
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suboptimal adherence suggests that these initiatives may be
important yet insufficient for fully addressing the barriers to
life-long adherence that many patients face.15,16
Adherence improvements found in trials that have tested
multi-component interventions lend further support to the
complexity of this behavior.17 Social-ecological models of
ART adherence have been tested among pediatric and ado-
lescent HIV patients,18,19 showing a range of barriers to ad-
herence to address at the individual and caregiver levels.
Similar models are needed among adults and older adults to
guide understanding of the shifting struggles of ART adher-
ence over time in a patient’s illness.
In this study, we adapted a contextualized approach to
understanding factors that influence adherence, following the
work of Broyles and colleagues who suggest replacing the
dichotomous concept of adherence and its narrow focus on
the patient with the concept of ‘‘medication practice’’ in
order to create space for understanding the influences of
power structures and institutions on ART medication tak-
ing.20 By opening up this space for patients to describe their
medication taking practices at present and to reflect on how
these practices change on a day-to-day basis and over longer
periods of time, we aimed to gain a more nuanced under-
standing of ART adherence and inform improved patient care
and interventions for supporting optimal, sustained medica-
tion taking.
Methods
From February to July 2012, we conducted six 2-h focus
group discussions among 56 PLWH receiving ART. Two
focus groups were held in each of three geographically dis-
tinct regions of North Carolina, selected to represent a large
metropolitan area, a small city, and a rural area. Focus group
guides were developed to explore perceptions regarding the
HIV diagnosis experience, ART initiation decisions, and
facilitators and barriers to ART adherence. Three groups
were held with all men, one with all women, and two were
mixed gender. One group was held with Spanish speakers.
Participants completed a brief paper survey at the start of the
focus group for sociodemographic characteristics and ART
history. Survey responses were entered into an Excel file and
SPSS version 21 was used to compute descriptive statistics.
Focus groups were recorded and transcribed verbatim. The
Spanish transcript was translated by a bilingual Spanish-
English speaker. A team of five researchers trained in qual-
itative data analysis worked together to identify themes
across the six focus groups and code and analyze the data.
First, each transcript was read by all team members to
identify themes within the predetermined focus group guide
questions (e.g., facilitators and barriers to adherence) as well
as emergent themes (e.g., ‘‘the process of becoming adher-
ent’’). These themes were used to create a codebook that
included one or more codes to capture each theme, a defini-
tion for each code, and illustrative sample quotations. This
codebook was then uploaded to the Dedooseª web-based
qualitative data analysis software and used by all team
members to code Transcripts 1 and 2.
After each transcript was coded, the team resolved dis-
crepancies and inconsistencies in the application of codes and
further refined the codebook. This process resulted in a final
list of 33 codes. Transcripts 1 and 2 were then re-coded with
the final codebook and each remaining transcript (3 through
6) was read and coded independently by two coders. A third
coder reviewed all six transcripts to identify any remaining
inconsistencies, which were then discussed by the full group
to reach consensus.
To support analysis of relationships between codes, we
used the Memo and Code Co-occurrence functions within
Dedoose. Reports consisting of all coded blocks of text were
generated for each code as well as the most commonly co-
occurring codes. Syntheses were then written for each theme
based on its codes and key sample quotes were selected to
illustrate the theme. We drafted conceptual models to un-
derstand how themes were related and used these to guide the
presentation of results within this article.
This research is part of a larger study, The Estimation
Antiretroviral Medication Adherence (ESTEEM) Project,
focused on the development of a brief clinical screening tool
for predicting future ART adherence. The University of
North Carolina Biomedical Institutional Review Board ap-
proved this study. Participants chose pseudonyms to use
during the focus group to protect their confidentiality.
Results
Sample characteristics
To contextualize the qualitative findings, Table 1 lists the
demographics and ART history overview of focus group
participants by study site. Participants included 1 transgender
woman, 21 female, and 34 male HIV-positive participants, of
whom 43 were black, 7 white, 3 Hispanic, 1 Native Ameri-
can, and 2 participants of other race/ethnicity. Average age
was 49.9 years old (range, 23–67 years) and mean years
living with HIV was 14.7 (range, 3–28 years) with some
variation across sites. A quarter of participants reported
missing one or more of their prescribed ART doses in the past
month.
Overview of qualitative themes
Participants’ discussions about ART reflected a fluid and
complex nature of taking HIV medications as they talked
about how they learned through trial and error to take their
medications in ways that worked for their day-to-day lives.
They described phases of taking and not taking medications
infused with language that reflected power and control
struggles across numerous arenas (Table 2). ART adherence
was a central behavior through which these power dynamics
operated, revealing aspects of intentionality in medication
taking practices that functioned beyond—and in addition
to—the goal of treating one’s HIV infection. These pro-
cesses were facilitated and shaped by participants’ life
contexts, especially managing multiple co-morbid condi-
tions, navigating complex social welfare systems (e.g., the
AIDS Drug Assistance Program—ADAP), and coping with
HIV stigma.
For a number of participants, how they took (or did not
take) ART became an assertion of personal agency—whether
health-promoting or self-destructive, whether consciously or
unconsciously. Four arenas where power and control strug-
gles appeared most relevant for HIV medication adherence
emerged from the discussions: (1) struggling against HIV
disease; (2) struggling with ART and one’s own body; (3)
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Table 1. Sociodemographic Characteristics of 56 PLWH from Six Focus Groups
Site 1 Site 2 Site 3 All
N = 18 N = 19 N = 19 N = 56 (%)
Age in years
Mean 48.9 52.0 47.2 49.9 (6.81)a
Range 42–57 23–67 40–60 23–67
Gender
Male 11 13 9 33 (58.9)
Female 7 5 10 22 (39.3)
Transgender 0 1 0 1 (1.8)
Sexual orientation
Gay 8 9 3 20 (35.7)
Lesbian 1 0 1 2 (3.6)
Straight 6 10 14 30 (53.6)
Bisexual 2 0 1 3 (5.4)
Other 1 0 0 1 (1.8)
Race/ethnicity
Black 17 12 14 43 (76.8)
White 0 5 2 7 (12.5)
Hispanic 0 0 3 3 (5.4)
Native American 1 0 0 1 (1.8)
Other 0 2 0 2 (3.6)
Mean years living with HIV 20.1 16.3 11.2 14.7 (7.69)b
Missed ART dose, past month 5 3 6 14 (25.0)
On initial ART regimen 7 5 8 20 (35.7)
Has health insurance 14 14 12 40 (71.4)
aMean age in years = 49.9 (standard deviation = 6.81).
bMean years living with HIV = 14.7 (standard deviation = 7.69), range: 3–28 years.
ART, antiretroviral therapy; PLWH, people living with HIV/AIDS.
Table 2. Arenas of Power and Control, Relevant Sub-themes, and Illustrative Quotes
Struggling against HIV disease
Desire for control over one’s life and death, fear of ART, fear of death
Denial of HIV status
Beliefs about HIV, CD4, and viral load
Beliefs and skepticism about how ART works against HIV
Example: ‘‘My brother, I saw all his friends, just fell off the map one by one.Why, should it [ART] work for me, it didn’t
work for the last 20 people that died.so I disobeyed the medicine at first and said, at least I’m gonna go [die]
comfortable.’’ (Participant #49, male, age 48)
Struggling with ART and one’s body
Pill burden
ART’s perceived impact on the body, side effects attributed to ART (past and present)
Developing medication taking practices that work for one’s life
Managing co-morbid conditions
Example: ‘‘You just get sick and tired of feeling terrible from taking the medicine sometimes. and just want a relief from it
and I have quit for that very reason. The medicine makes you feel so terrible, you just give up on it and quit for a while.’’
(Participant #20, male, age 61)
Struggling with ART and healthcare providers
Perceived limited treatment options, shock at diagnosis
Tensions with providers (stigma, paternalism, mistrust, misrepresenting ART taking practices)
Advocating for and educating oneself
Supportive providers
Example: ‘‘I actually ask my doctor a lot of questions. I made him, I basically made him tell me what I wanted to know.He
told me that, that I would be taking 12 pills a day.I said I can’t do that and I won’t do that. So I basically made him do
his research.He got to the point where he found three pills that I can take.’’ (Participant #1, female, age 44)
Limited control within multiple systems
Maintaining access to medications (pharmacy problems, drug assistance programs, co-pays)
Unintentional treatment interruptions (incarceration, hospitalization, life events)
Example: ‘‘Every year you gotta redo your ADAP. Cut that out man! We aren’t going to get rid of it [HIV].so why I got to
keep going each year.if you can, cut that out.’’ (Participant #24, male, age 46)
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struggling with ART and health care providers; and (4) ex-
periencing limited control within multiple systems.
Despite overlaps and interrelationships across these are-
nas, we find this framework useful for organizing the per-
sistent themes that dominated focus group discussions, and
for demonstrating that power dynamics were operating across
multiple areas in relation to medication adherence. Table 2
presents this framework, along with sub-themes drawn from
the coded text, and supporting sample quotations from the
transcripts. Each of the four arenas and sub-themes are de-
scribed in turn below.
Struggling against HIV disease: ‘‘Not taking the meds
kept me in a safety zone of denial.’’ (Participant #12,
male, age not reported, put off starting ART for 18 years)
We identified four sub-themes related to struggling against
HIV disease: strong fears of ART and death that prompted a
desire for control over one’s life and death, denial of one’s
HIV status, beliefs about HIV, CD4, and viral load, and be-
liefs and skepticism about how ART works against HIV
(Table 2).
After diagnosis, most participants described facing over-
whelming fears of death, HIV, and ART itself. As the majority
of participants had been living with HIV for over 10 years,
most knew HIV-infected people who had died while taking
ART. Participants described struggling with this knowledge
to understand the relationship between HIV, ART, and death.
Participants used words like ‘‘poisons,’’ ‘‘toxic,’’ and ‘‘dan-
gerous’’ to describe ART drugs—especially earlier regimens.
Fears and skepticism about the effectiveness of ART were
consistent themes across all six focus groups. In coping with
these fears, a common response described by participants was
a desire to take control over one’s own death (and life) through
intentionally choosing to take or not take ART:
My brother, I saw all his friends, just fell off the map one by
one.Why should it [ART] work for me, it didn’t work for the
last 20 people that died.so I disobeyed the medicine at first
and said, at least I’m gonna go [die] comfortable. (Participant
#49, male, age 48)
Q: Let me make sure I understand, what helps you take your
[ART] on time is that you found that you tried to commit
suicide and couldn’t do it?
Participant: Uh huh. God, if you can’t kill yourself, why you
going to let somethin’ else do it? (Participant #31, male, age
49, describing the relationship between three suicide attempts
and his current adherence to ART)
Initial fears of HIV, ART, and death were also common
among participants who were more recently diagnosed.
Furthermore, even for participants who were reflecting back
15–20 years ago, their discussions were very clear, detailed
memories of a diagnosis event that continued to impact their
life every day since diagnosis.
Alongside fears of death, HIV, and ART, a number of par-
ticipants described a struggle coming to terms with the dual
concept of HIV infection as a life-threatening condition, and
manageable through medication. For these individuals, denial
of their HIV status kept them from care and from taking ART:
I was in denial. I didn’t want nobody to know I had HIV for a
long time. So that kept me away from the doctors. I hid it. I
knew I had it, but I didn’t want to face it. (Participant #49,
male, age 48)
For some participants, struggle with denial of their status
and desire to avoid or stop taking ART resulted in endorsing
the belief that they were ‘‘different’’ and would not need
medication:
You want to think that you’re different, you’re cured. You know
that’s what I want to think, you know I’m good and I’m spe-
cial.I feel better now. (Participant #3, male, age not reported)
I felt like I was doing good. Every time I came to get it checked,
everything checked out fine; I said maybe I’ll just wean myself
off of them [meds] and . might not have to take them. So I did.
(Participant #41, female, age 45)
Feeling healthy allowed some participants to remain in this
state of denial. As described by Participant #33: ‘‘I had went
like two and a half, three years without [meds].because I
was undetected. I became undetectable. No, I don’t need it
[ART]. Why should I?’’ (male, age 49).
In contrast, ART caused side effects that made partici-
pants feel sick. This dissonance meant that for many par-
ticipants there was a need to come to terms with new
understandings of what taking medication meant, including
that they would need to take medicine even when they did
not feel sick; that, even if they did feel sick, taking medicine
might not make them feel better; and that the side effects of
medications might make them feel sicker. Some participants
explained how they could test these concepts by taking and
not taking medication:
I want to go a whole 60 days.without taking medication.
Period. And see how it will [work]. (Participant #5, female,
age 52)
I can sort of like feel it [HIV] in my face.feel it in my mouth,
you know when that disease is prevalent or high. And when
I’m feeling great, I don’t feel it. I want to test it [not take
medication] and see if I’m gonna feel like this for a while
anyway. (Participant #3, male, age not reported)
I feel good, as far as taking that stuff [ART], I’m confident. I
know I’m feeling better.If I missed it for 3 weeks, I felt bad,
you know. I can feel the change coming in my system. (Par-
ticipant #24, male, age 46)
The examples above also illustrate the beliefs participants
developed about how ART and HIV worked. These con-
versations generally reflected a mixed language of medical
terminology and sensory experience. As suggested by Par-
ticipants #33 and #41 above, and described further below,
depending on a person’s beliefs about how ART and HIV
worked, good test results could deter or support medication
adherence.
Struggling with ART and one’s body: ‘‘You just get sick
and tired of feeling terrible from taking the medicine’’
(Participant #33, male, age 61)
The second arena in which power, control, and in-
tentionality affected adherence focused on ART’s perceived
and experienced effects on the body. Important sub-themes
included high pill burden, ART’s perceived impact on the
body, side effects attributed to ART (past and present), de-
veloping medication taking practices that work for one’s life,
and managing co-morbid conditions.
For many participants, side effects were described as sig-
nificant barriers to adherence that wore people down physi-
cally and emotionally over time:
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Really you just get sick and tired of feeling terrible from taking
the medicine sometimes.and just want a relief from it and I
have quit for that very reason. The medicine makes you feel so
terrible, you just give up on it and quit for a while. (Participant
#33, male, age 61)
I stopped. I mean I was just so nauseated and just so sick and
it’s like I was tired of taking it; I was sick and tired of taking
medicine. (Participant #42, female, age 45)
The severity of side effects and participants’ inability to
control them led to intentional decisions to stop taking ART at
various time points. While some participants described physi-
cal symptoms which limited their functioning (e.g., daily di-
arrhea which precluded work or taking public transit), others
dreaded bad dreams, or attributed depression to their ART.
Taking pills all your life like this.it bothers our mentali-
ty.(Participant #2: We’re depressed.) I’m telling you it’s
very depressing, you got to take it every day, every day, every
day, and that’s not every day living. And sometimes you want
to say Lord, I want to take a break. I’m tired of taking pills.
(Participant #5, female, age 52; Participant #2, female, age 49)
Consequences! If you don’t take it, this is what hap-
pens.Throughout my whole life it’s been: if you don’t do this,
you get consequences.I do want to live, but I also want to live
a quality of life. I don’t want to live dragging through the mud.
(Participant #12, male, age not reported)
As suggested above, some participants felt a sense of
powerlessness in the face of their ART regimens’ impact on
their physical and emotional lives. Some wearied of—and
pushed back against—the constraints that accompanied rigid
medication regimens, such as having to schedule meals and
social lives around their pill schedules.
Thus, taking ART involved intentionally developing
medication-taking practices that worked for participants’
bodies and their lifestyles. As medication regimens and side
effects interrupted participants’ lives, they re-asserted control
by intentionally altering how, when, and whether they would
take their medication.
My best advice is, don’t let the meds rule you. Yes, I take my meds
daily, twice a day. I try to take them between six in the morning
and eight, and the same, in the afternoon. If I don’t take it right at
six I don’t worry about it. When I think about it, I take it. I didn’t
let the meds rule my life. (Participant #19, male, age 62)
I used to just tell myself, ‘‘Oh, it’s casual Friday. I won’t take
the pills today.’’ (Laughter) That was my reasoning. So once a
week I would just miss pills. And I never was on a schedule. I’d
take mine when I remember in the morning. (Participant #25,
male, age 56)
Here participants #19 and 25 describe examples of the
intentional decisions which were within participants’ power
to make and resulted in their regaining control of how ART
would factor into their lives.
Newer, simpler ART was generally perceived as less toxic
and described as producing fewer side effects, facilitating
greater acceptance of ART among many participants. How-
ever, in all six focus groups there were participants who
continued to experience side effects with their current regi-
mens (e.g., nightmares, diarrhea and other gastrointestinal
problems, vomiting, nausea, sweating, and racing heart beat)
that they attributed to ART. In the following two quotes, both
participants describe continued struggles with their once-a-
day regimens:
I only take one pill, one pill at night, okay.But, thank God,
the only side effect of that is I have real crazy dreams,
nightmares type situations. (Participant #12, male, age not
reported)
I still have the side effects, the nightmares, the sweats, the
cramping, throwing up and stuff.the problem with it [is] I
have to take it every day at the same time. (Participant #2,
female, age 49)
Side effects led some participants to ask their doctors to
switch them back to more complex regimens (e.g., from one
pill once a day to multiple pills multiple times a day). Others
tried to rearrange their lives and medication taking practices
to accommodate their current regimens (e.g., not taking pills
at night that caused nightmares), or simply skipped doses as
needed.
Some participants believed there were connections be-
tween their HIV medications and longer-term side effects in
the form of other health conditions. These beliefs placed
individuals in the position where they felt that following their
prescribed HIV treatment was exacerbating or causing other
health conditions.
I started getting depressed.and I had never known myself to
be depressed and I actually thought it was the medica-
tion.that was making me depressed so I took a break for
about a month. (Participant #1, female, age 44)
When I started taking the HIV medicine, I developed diabetes,
high blood pressure and all that, which I never had none of
it.and there wasn’t none in my family.what they don’t tell
you, the HIV medicine you taking end up causing you more
health problems and you end up taking medicine for that
too.And I just get fed up with taking all them pills all the
time. (Participant #22, male, age 42)
As seen above, beliefs about ART’s impact on broader
health led some participants to intentionally stop taking ART
at times, while others became frustrated, discouraged, or
mistrustful.
Struggling with co-morbid conditions was the most con-
sistently mentioned barrier to adherence discussed exten-
sively by the majority of participants in all six groups (Table
3). Thirty-five participants described at least 69 different health
conditions other than HIV. Since a detailed medical history was
not collected for each participant, this is likely an underestimate
of the total burden of co-morbid conditions among our sample.
Trying to keep control over other chronic co-morbid health
conditions and HIV presented additional complexities im-
pacting participants’ ability to take ART as prescribed:
I take something like 14 different medications, can you
imagine opening the bottles and going through 14 medications
twice a day.it would take over your whole day just about
going through medication bottles.I probably skipped medi-
cations many times because I didn’t have time to fool with
going through the bottles. (Participant #20, male, age 61)
I have other issues going on with severe depression and
PTSD.I take this medicine to stop the nightmares and help
you go to sleep.on Ritalin and the anti-depressants.I take
about 10 or 12 medicines a day, but only three of them are
related to the HIV. (Participant #28, female, age 55)
The most common current co-morbid conditions discussed
were depression, heart conditions, and diabetes. Depression
and substance use (generally referred to as a past problem)
were described as particularly interfering with taking ART.
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My depression got so severe that I just wanted to die. I stopped
taking my meds altogether; that’s when my T-cell count
dropped to 12. My viral load was off the charts because I
didn’t want to live anymore.there’s a lot of things that goes
through your mind; you’re like oh my God, I’m so sick and
tired of taking this medicine, I just want to die. I don’t care.
(Participant #53, male, age 57)
In my process of me taking my meds, I had to understand
and realize that I couldn’t do the dope, I couldn’t do the
drugs no longer, I couldn’t do the alcohol (Participant #9,
female, age 52)
The majority of participants in this sample had other co-
morbid conditions in addition to HIV. The process of trying
to become or stay adherent to ART thus involved finding
ways to take ART that worked with their other evolving
health conditions, leading at times to medication taking
practices different from what was prescribed. In some cases, a
lifestyle change was necessary to accommodate ART, while
in other cases participants altered their medication taking in
an attempt to avoid short or long-term side effects, or simply
were not able to successfully manage these multiple condi-
tions at certain times (e.g., Participant #53 above).
Struggling with ART and healthcare providers:
‘‘[Doctor] said take it on an empty stomach. I wouldn’t.
I would at least eat a cracker, and that seemed to help
me tolerate meds.’’ (Participant #19, male, age 62)
In discussing interactions with healthcare providers, par-
ticipants described the trauma and shock of their initial di-
agnosis, feeling that they had limited treatment options, and
tensions with providers, as well as strategies they used to
advocate for themselves, and the supportive provider rela-
tionships that helped facilitate adherence.
For most participants, their HIV diagnosis was a traumatic
experience, exacerbated by interactions they perceived as
cold or stigmatizing.
[Health Department worker] just point blank said, ‘‘You’re
going to die in less than a year. You can’t have sex, you can’t
do.’’ She was real nasty. (Participant #25, male, age 56,
diagnosed early 1990’s)
The doctor that told me I had HIV, he was very cold. You know,
like I was nothing. I was in a coma. I woke up and he’s standing
over me and he says, ‘‘Oh um, you know you have HIV. Here’s
your prescriptions’’. And he just walked away. This is 2007
and this was in Boston! (Participant #32, female, age 59)
These two diagnosis experiences occurred about 15 years
apart, yet both recall strained patient-provider interactions.
In addition, many participants described being in a state of
shock upon receiving their results including difficulty pro-
cessing information, reduced hearing, feeling numb, and
shutting down. During this time, they were being presented
with a large amount of information or being asked to make
choices about their treatment that they could not process.
My first reaction when the doctor informed me that I was HIV
positive, it was a blank stare, I shut down.I was in shock
(Participant #47, female, age 43)
I had a kind of core blank feeling because I couldn’t accept
that it was me. I almost was feeling numb (Participant #13,
male, age 45, all other seven participants in his group nod in
agreement)
Importantly, the healthcare provider who gave an initial
diagnosis was often not the doctor who would eventually
Table 3. Co-morbidities Described (Unprompted) by 56 HIV-Infected Focus Group Participants
Condition (as described by participant) Participant ID numbers Total
Diabetes 19, 22, 25, 26, 34 5
Kidney disease 42 1
Stroke 7, 8, 11, 33 4
Seizure/epilepsy 8, 21 2
Neuropathy, chronic pain 8, 36 2
Heart disease 7,a 8,a 19, 24, 26, 56a 6
High blood pressure 19, 22, 34, 42, 48, 53, 54 7
High cholesterol 19, 53, 56 3
Addiction/substance useb 9, 29, 34, 35, 40, 42, 45, 49, 53 9
Depression 1, 3, 28, 31, 41, 47, 53, 56 8




Memory loss/amnesia 5, 8c 2
Sleep disorders 28, 36 2
Cancer 7d, 21d, 27,e 39f 4
Asthma 54 1
Unspecifiedg 3, 20, 24, 28, 29, 31, 42, 53, 56 9
Any co-morbid condition 35 unique individuals 69 conditions
aParticipant mentions specific hospitalizations for ‘‘heart attack.’’
bThe majority of participants who described addiction/substance use framed it as something they had to overcome in order to become
adherent to ART, and/or as something they turned to earlier on in their diagnosis to cope with the diagnosis and/or remain in denial about HIV.




gApplied if a participant describes taking daily medications for a condition other than HIV but does not specify the condition.
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provide care. However, participants’ descriptions of their
negative diagnosis experiences were linked in many cases to
a trajectory of care involving future avoidance of doctors and
delayed ART initiation.
After receiving their diagnosis, participants described
feeling like they had limited control over the treatment op-
tions and choices presented to them. Most participants did not
describe their doctors as decision-making partners, nor did
they describe themselves as compliant or good patients. In
some cases, they felt powerless as physicians presented them
with options that were not actual choices about when to start
ART or how to take medication:
I felt I was a number during the diagnosis.It was something
that was set out before me and it was almost like being on a
treadmill, where it was rolling and there was nothing I could
do to stop it.So what choice did I have? (Participant #15,
male, age 47, talking about whether he felt like he had a choice
when initiating ART)
I remember the doctor telling me; ‘‘If you don’t take it, don’t
take it today and then take it tomorrow, just stop taking it
completely.’’ And that’s what I would do. I would just stop
taking it. And I would take it and go a month at a time without
taking it, but when I’d go get blood work done, the next thing I
know she’s calling me, ‘‘Well [name redacted] you’re not
taking your medicines.’’ (Participant #42, female, age 45)
Diagnosis shock combined with perceived limited options
turned many participants off to care, while leaving others
feeling unprepared to start ART or unsupported in taking
ART as prescribed.
In addition, patient–provider interactions involved nego-
tiations where issues of power and control were very much
present. Healthcare providers’ power was centered in their
medical authority, prescribing power and possession of in-
formation. Yet patients also exerted power within the doctor–
patient relationship. For example, participants acknowledged
misrepresenting their ART taking practices to providers,
avoiding appointments, and trying to outsmart blood tests:
Q: When you took your break, did you talk to your doctor
about it?
Participant: No. Because I didn’t want him to yell.(laughter)
I didn’t want, I didn’t want to have to hear what he had to say
when I went, you know, to, to see him. (Participant #15, male,
age 47)
[I’d] take the medicine [only when] it was time to go to the
doctor. Like if I’m supposed to go to the doctor on Thursday,
I’ll take it Tuesday, Wednesday, and Thursday so it will be in
my system.knowing that he could look at the blood work and
tell when you was taking the medicine. (Participant #17, male,
age 53)
Some participants also advocated for themselves, negoti-
ating for a more simplified regimen or to change medications
to avoid specific side effects.
I actually ask my doctor a lot of questions. I made him, I
basically made him tell me what I wanted to know.He told
me that, that I would be taking 12 pills a day.I said I can’t do
that and I won’t do that. So, I basically made him do his
research.He got to the point where he found three pills that I
can take. (Participant #1, female, age 44)
This statement highlights how healthcare providers were
perceived to control information and knowledge. Many par-
ticipants’ descriptions about acquiring knowledge about HIV
and ART reflected a process of (re)taking some of this control
and creating a more equal power balance.
Importantly, when discussing how doctors supported ART
taking practices, some participants described the importance
of their healthcare providers being caring, compassionate,
and understanding. In participants’ discussions about pro-
viders, supportive relationships engendered trust and en-
couraged medication taking:
My doctor was the lovingest, most compassionate doctor and
he was concerned. That’s what made me really think about
taking [ART] because he was really concerned about the
person. (Participant #37, female, age >50)
Q: What did your doctor say when you told your doctor you
stopped [ART]?
Participant: To be a 100% fair with you, I don’t think he
chastised me too hard.I think he sort of understood because
it had been so long. (Participant #20, male, age 61, describes a
4 month break in ART)
Following their physicians’ lead, participants embraced
the clinical language of CD4 cell counts and viral load levels
as primary indicators that ART was working for them. A
number of participants described how these numbers helped
them keep taking ART.
Every time I go to the doctor, they tell me my CD4 count.and
the virus is undetectable.. That just encouraged me to keep
right on doing right. (Participant #35, male, age 60)
She [doctor] always tell me how well I’m doing with it. She’s
like ‘‘wow’’.and I actually kept the card, so I got these
[CD4] counts. I look at them.and it’s so great and she’s so
thrilled with it and so am I. (Participant #13, male, age 45)
Of note, the quotes above illustrate how ‘‘good counts’’
(CD4, viral load) helped some individuals persist with
taking ART as prescribed, in contrast to tempting them to
wean themselves off medications, as described earlier in
the results. This contrast points to the importance of
patient-provider communication and awareness of nuances
in patients’ understandings of how ARTs and HIV operate
within the body.
Limited control within multiple systems: ‘‘Who in the
world can pay $2000 a month for pills?’’ (Participant
#24, male, age 46)
The final sub-theme raised across all focus groups centered
around participants’ limited control within the multiple
systems they experienced as part of their medical care
and day-to-day lives. Maintaining access to medications was
challenged through pharmacy problems, drug assistance
program logistics, and multiple copayments. Unintentional
treatment interruptions were also common particularly around
both major and minor life events including travel, hospital-
ization, and incarceration.
Maintaining access to medications through logistical is-
sues with pharmacies and drug assistance programs, as well
as affording co-payments, posed problems for a number of
participants. For some, these problems were as basic as
learning to place prescription refills sufficiently ahead of time
to account for pharmacy stock-outs. For others, navigating
the program requirements for Medicaid and the AIDS Drug
Assistance Program (ADAP) were viewed as unnecessarily
complicated barriers to receiving ART:
612 MUESSIG ET AL.
It takes.4 months to 8 months to get on medication in [city
name redacted]. you get processed and you have to go see
this one for 8 hours, you got to go see the doctor for this. you
got to go see the case worker. And they give you this little card
and it say that every 6 months, or every so often you come and
get this renewed.keep everything in line. Once you mess up
and you miss that date they cut you all off. So that kept me off
for like a, almost a year. (Participant #51, male, age 47)
Every year you gotta redo your ADAP. Cut that out man! We
aren’t going to get rid of it [HIV].so why I got to keep going each
year.if you can, cut that out. (Participant #24, male, age 46)
A few participants also described the difficulties they faced
in making sure they could still receive free medications when
their ART regimens changed.
Shorten the forms so that you won’t have to put so much
information down and.if you’re on a certain type of meds,
and then they switch you up and then you have to go and fill
out another form for those meds.every time they switch you
off a drug then that forces more forms that you have to fill out.
(Participant #27, male, age 49)
If you got the kind of insurance I got, it takes 2 to 3 months for
them to okay you, before you can get a prescription. And you
can’t afford this medicine out of your own pocket. It come to
the point, am I going to pay my rent or do I want to get this
medicine? (Participant #22, male, age 42)
Since ADAP often mails ART medications to patients’
homes, participants who traveled or moved could experience
inadvertent treatment interruptions, which also caused emo-
tional stress and time to resolve.
A few participants mentioned personal financial barriers to
receiving medications, while more expressed concern that
others (though not them) could not afford ART medications.
Talk of personal costs primarily focused on medication co-
payments. Given the large number of co-morbidities described
by participants in Table 2 above, it is not surprising that co-
payments could add up to a substantial monthly expense.
All of us don’t have the money to pay for that copay-
ment.some drug stores will charge you five dollars, some
charge you ten, some charge you three; you still don’t have the
money. They think Medicaid pay for all of them but it really
don’t. (Participant #7, female, age 45, on 16 different medi-
cations with total monthly co-payments of $160–$180)
[ART] cost you.especially co-pay. I don’t have Medicaid
and.the medications, you know they are very costly. I’m on a
fixed income.a lot of times I can’t afford it.I was able to get
with the ADAP program, but there’s still some.costs, still
costly.couple thousand dollars.out of pocket. (Participant
#8, female, age 52, describing annual cost of care)
Although financial barriers to accessing medications were
only mentioned by a few participants, others expressed
concern and fear about their lack of control over their ability
to indefinitely receive free ART.
It wouldn’t surprise me that when you come for this [ADAP]
signing up every year, or now I heard 6 months, they didn’t tell
you, you know we can’t fund it.that you gotta get cut off
because you make this and this [salary].with the way the
economy and the cut backs here, it’s kind of a scary thought in
the back of your head. (Participant #23, male, age 43)
There’s been a huge cut back for the ADAP medication that’s
covered. It used to be every one of my meds was covered. Now
it’s just four.Next year I’ll probably be eligible for Medicare
and that’s going to be a whole new ball game. (Participant
#19, male, age 62)
Similarly, one participant who was returning to work after
having been unemployed shared his concern that he could not
afford to work because he would no longer be eligible for ADAP
and the co-payment for ART in his employer-based health in-
surance would be too expensive. These fears added stress and
worry as participants described knowing their monthly sup-
ply of ART would cost thousands of dollars if not subsidized.
Life events including incarceration, hospitalization, and
public assistance systems limited participants’ abilities to make
decisions regarding their health, and in numerous instances in-
terrupted their access to HIV treatment. Some people talked
about treatment interruptions caused by short- or long-term
hospitalizations, which were a common occurrence.
I was in the hospital for a very long time and a nursing home,
there was times that I didn’t get my medication on time or
twenty-four hours later. Being in the hospital, sometimes
you’re subject to not getting your medicine when you should.
(Participant #21, male, age 67)
Being in the hospital for a number of times, and even though
you tell them the regiment that you’re on and the times that
you take it, usually it’ll happen where you’re not getting it for
a day or so and you miss out. Or, in my case, I was in a coma
for a couple of weeks and I didn’t get any meds. (Participant
#27, male, age 49)
Given the large number of co-morbid conditions partici-
pants experienced, problems of access to medications within
hospitals were a serious concern.
Five out of six participants who had been incarcerated re-
layed examples of having diminished control over their ART
treatment options while incarcerated. They recounted not
having a choice regarding when or how to take their medications,
and how their HIV-positive status was disclosed to prison staff
or inmates without their permission. Two participants shared
techniques that they used, such as hiding HIV medication pro-
vided to them by the prison system, to protect themselves from
stigma, discrimination, or targeting by fellow inmates:
Well, actually I was locked up (short laugh) and I would just
hide my meds.I didn’t want nobody to know I was taking HIV
meds. (Participant #13, male, age 45)
I was told when I went to prison that I had to keep my medi-
cations under lock and key.Because if those, the people in
the yard got whiff that I had Sustiva, they was going to come to
me to get it because it’s a form of hallucinogen. (Participant
#31, male, age 49)
For three other participants, entering the prison system
caused treatment interruptions ranging from 2 days to 3
weeks when they were unable to access their regular ART.
Discussion
These focus group discussions reflected how the rigid,
indefinite nature of participants’ HIV medication regimens
required them to enact a large amount of consistent control
within multiple systems. Yet participants described having
limited power within these systems, including regarding their
own body’s health and reactions to taking medications. Ul-
timately, ART adherence was the product of a complex set of
internal and external struggles and conditions. Many partic-
ipants felt that they had to look out for themselves against this
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disease, their treatment, and the systems that they encoun-
tered (e.g., ADAP, hospitals, prisons).
Participants intentionally adapted how they took ART to
work within their circumstances or lifestyles, and explained
struggling to maintain control of their health and healthcare.
In this process, their understandings and beliefs about ART
were important in determining how they took their medica-
tions on a daily basis and over time. Others have described
similar ART taking practices as adherence on a ‘‘dose-by-
dose basis’’ emphasizing multifaceted models influencing
how and whether a dose is taken.21 The persistence of fear
and mistrust around ART in this sample emphasizes the
importance of health providers seeking out and addressing
patients’ perceptions of the connection between medications,
side effects, and co-morbidities.
Participants’ intentional medication taking practices could
also be seen as a form of ‘‘self-tailoring.’’20 Self-tailoring of
prescribed treatment has been described as a form of self-
regulation within a variety of other conditions including
epilepsy,22 co-morbid chronic conditions,23 and chronic ob-
structive pulmonary disease.24 Our work contributes to this
literature by looking at how power, control, and intentionality
were at play across multiple areas of participants’ lives (not
just within the self and the patient–provider relationship) and
influenced ART medication taking practices.
Our results underscore the need to better understand and
adapt responses to patients’ perceptions of the impact of their
medication self-tailoring on their HIV health. We found a
range of understanding in this diverse sample from those who
‘‘tested’’ the impacts of not taking ART on their bodies, to
those who clearly articulated the connection between stop-
ping taking ART and changes in their viral loads. Patients’
interest (as compared to indifference) in how medication acts
on their bodies suggests opportunities for greater communi-
cation and intervention around medication taking.
Side effects were a commonly reported challenge across the
focus groups and contributed to the daily struggle many par-
ticipants had with medication taking. While many of these
experiences had occurred years prior, a number of participants
continued to report gastrointestinal and neurologic effects while
on more modern ART regimens. Some participants had worked
with their doctors to switch back to older regimens, while others
chose to bear these side effects—a choice that had implica-
tions for quality of life and achieving optimal adherence.
A connection might be drawn to recent work regarding
the negative impact of self-silencing (‘‘concealing feelings
to avoid conflict, loss, and protect self-esteem’’) on ART
adherence among women with HIV.25 Brody and colleagues
theorize that self-silencing could impede the communication
skills that patients need for building positive relationships
with their care providers.25 In the current sample, those who
are prone to self-silencing could experience the power im-
balance in their provider interactions more acutely; at the
same time, the unequal patient–provider relationship may
further reinforce patients’ self-silencing behaviors.
Other medical conditions featured prominently across all
focus group discussions and in individual participants’ nar-
ratives. This finding is consistent with a growing body of
literature describing co-morbidities among older adult HIV
patients and the new challenges multiple health conditions
present for healthcare and quality of life.9–11 Interventions
are needed that address HIV-infected patients’ longer-term
issues of HIV as a chronic disease and the challenges of
navigating their health and healthcare systems with HIV and
other chronic—and acute—conditions. Depression—the
second most common condition described by participants in
this sample—has been associated with higher number of co-
morbidities among HIV-positive older adults.26 Intentional
decision-making around ART also played a role here as some
participants felt that taking ART as prescribed was causing or
exacerbating their other health problems.
Health care systems and programs that provide medication
assistance, that is, systems designed to provide care, were at
times paradoxically oppressive, challenging participants’
agency for obtaining medications. Requirements for frequent
renewal of ADAP and other programs that provide access to
HIV medications were considered to be onerous and pre-
sented obstacles to adherence. Power and control operated
through ART taking practices in both health-positive and
health-destructive ways. At times, intentionally taking or not
taking medications became an assertion of agency, (re)-
claiming control within the few areas of participants’ lives
where they felt they had the ability to do so.
As argued by James Scott, within oppressive social ar-
rangements, those with less power find ways to give ‘‘the
impression of compliance without its substance’’ (1985, p.
26).27 This form of ‘‘everyday resistance’’ allows individuals
to ‘‘minimize compliance at the level of actual behavior’’
(Scott, 1985, p. 26) and maintain individual agency/control
within an unequal power relationship.27 Everyday resistance
by those who have less power is a sign that they are not fully
consenting to the position of powerlessness.27 Examples of this
could be seen in participants who described misrepresenting
their ART taking practices to providers, altered how they took
ART—including stopping entirely or trying to influence their
blood tests by taking medications in particular ways.
Findings from this study also connect with earlier work on
identity formation among PLWH. A 2012 focus group
analysis of patient–provider relationships among PLWH
found that stories of personal transformation and ‘‘autono-
mous motivation’’ were critical to the process of becoming
consistently adherent.28 As Laws and colleagues describe,
‘‘These participants.became adherent to medication regi-
mens and medical appointments only after undergoing per-
sonal transformations that represented incorporation of
illness identity, acceptance of the reality of their condition,
and a new or renewed sense of agency, including a will to
live’’ (p. 899).28 Our findings on power and control struggles
as barriers to adherence align with this work as participants
ultimately framed adherence as their own intentional deci-
sions or efforts within these power struggles.
For many participants, being adherent required accepting
an identity of having HIV—a process that took years for
those who faced shock, denial, and fear. The subsequent
behaviors required for perfect adherence are complex and
take on new moral dimensions within the power limitations
of multiple systems. For example, if one can only receive
their ART medication in-person, in-state, every 30 days, then
decisions about travel for work, family, or leisure also be-
come decisions about being a good patient and ultimately
a good person. These types of fraught decisions, alongside
the physical strains of coping with side effects and other
co-morbid conditions wore participants down over time—
a theme echoed in focus groups among other older
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HIV-infected patients.12 Resilient patients who are able to
achieve high adherence despite this multitude of struggles lend
further support to recent work on the positive relationship be-
tween resilience, ART adherence and virologic suppression.29
These focus group discussions revealed how the meaning
of ART adherence in one’s life is inadequately described by a
dichotomy of adherent/nonadherent. In the course of a pa-
tient’s illness, medication taking practices changed on a day-
to-day basis and over time. Vervoort and colleagues discuss
the role of acceptance of one’s HIV status leading to either a
determination to be adherent, or to ART being ‘‘subordinate
to other priorities in life.’’30
Adherence practices then follow from this position, lead-
ing the ‘‘ART determined’’ group of patients to overcome
challenges to adherence, while the other group will be se-
lectively adherent depending on how disruptive adherence is
to their lives.30 While our results support this conclusion, we
also found that the process of becoming and staying adherent
was more fluid and complex than simple determination or
subordination. Those who provide HIV care may need to
adjust adherence messages to reflect patients’ experiences of
medication adherence as a process rather than a fixed state.
There are a few limitations to this study. First, we utilized a
qualitative convenience sample, which is not representative of
the full scope of ART-taking patient experiences and medica-
tion taking practices. However, the sample did include partic-
ipants from multiple sites across a range of ages, gender, sexual
identity, and race/ethnicities. Second, we did not include newly
diagnosed PLWH or those not currently taking ART. We did
ask participants to reflect back to their diagnoses and did in-
clude participants who had started, stopped and restarted ART.
A future study could compare the adherence barriers faced by
patients who are newly diagnosed on ART or who have stopped
(and not restarted) ART with those on ART.
Lastly, participants’ narratives are subjective descriptions
of experiences as they understood them at the time of the
focus group. These narratives may be affected by social de-
sirability bias, recall bias, and participants’ interpretations of
their experiences, which may change over time. The focus
group method helps build validity of our analysis as we found
a large amount of agreement among participants within and
across groups, however future quantitative studies are needed
to test the relationships between barriers we identified and
ART adherence.
Power and control struggles in medication adherence prac-
tices are well-documented within the history of medicine.31
The shift from ‘‘non-compliance’’ to ‘‘adherence’’ language
suggests a move toward acknowledging the need to alter the
power dynamics we found so pervasive in these focus group
discussions, but more intentional work is needed. Measures
could be incorporated into clinical care and public health in-
tervention to address perceived power struggles and reduce
pressures on patients that may be driving practices of exerting
control via medication taking—and not taking—practices.
At the same time, we have attempted to emphasize the
power and control struggles that patients faced across mul-
tiple sectors in order to avoid what Broyles and colleagues
caution against: ‘‘a counter-productive anti-medicine orien-
tation where blame is shifted from the individual to the pre-
sumably insensitive, resistant clinician’’ (p. 374).20 As
demonstrated in our findings, patient–provider relationships
were only one component in a more complex process of
medication taking practices. Continued health policy and
coordination of care work is also needed to simplify the
multiple systems and institutions with which patients interact
and facilitate improved management of HIV infection and
co-morbidities.
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